INOVIO Pharmaceuticals Unveils $75 Million Public Offering for DNA Medicines

INOVIO Pharmaceuticals Launches Significant Public Offering

INOVIO Pharmaceuticals, Inc., headquartered in Plymouth Meeting, Pennsylvania, has announced a notable public offering to raise approximately $75 million. The company's focus on developing and commercializing DNA medicines has positioned it as a significant player in the biotechnology landscape, particularly in combating HPV-related diseases, various cancers, and infectious diseases.

On November 5, 2026, INOVIO revealed details of this offering, which consists of approximately 58.7 million shares of its common stock priced at $1.05 per share, alongside pre-funded warrants for an additional 12.7 million shares available at $1.049 each. The company has assigned Jefferies and Piper Sandler as joint book-running managers for the offering. Moreover, there is a provision for underwriters to purchase an additional 10.7 million shares within 30 days at the public offering price, indicating a solid interest from the investment community.

The projected closing date for this public offering is around November 9, 2026, contingent upon customary closing conditions being satisfied. These funds are expected to provide INOVIO with a substantial boost to enhance its research, development, and commercialization processes within the DNA medicine sector.

With ongoing concerns about HPV and its associated diseases, INOVIO's mission takes on heightened relevance. The biotechnology firm aims to leverage its innovative technologies, which focus on optimizing the design and delivery of DNA medicines, to empower the body's immune system to effectively fight off diseases.

As part of their strategic approach, INOVIO is committed to ensuring compliance with all regulatory requirements, having filed a shelf registration statement with the Securities and Exchange Commission on July 2, 2026, and received effective status by July 10, 2026. This diligence is crucial as it paves the way for the offering to unfold within the regulatory framework of the SEC.

To navigate through this public offering and actively engage prospective investors, INOVIO has made available resources including a preliminary prospectus supplement and an accompanying prospectus, which can be accessed through the SEC’s official website. These documents detail the terms of the offering and provide further clarification about the trajectory of the company's initiatives.

As we look towards the outcomes of this offering, stakeholders are reminded of the inherent uncertainties aligned with forward-looking statements, which encapsulate broader expectations about future events and financial results that may diverge from initial projections. The risks associated with market conditions and the successful completion of the offering are similarly highlighted.

In conclusion, this public offering not only underscores INOVIO Pharmaceuticals' ambitious initiatives to secure capital but also reinforces its commitment to pioneering advancements in DNA medicine to combat pressing health challenges. Investors and industry analysts alike will be observing the company's forthcoming actions and performance as it aims to translate the funds raised into impactful medical solutions.

For more information regarding INOVIO Pharmaceuticals and its offerings, interested parties can reach out to specified contacts provided in their press releases. As the biotech industry continues to evolve, investors will be keen to see how INOVIO will navigate the complexities of this funding round and advance its business objectives in this critical health sector.

Contact Information:
Media: Josephine Galatioto - ICR Healthcare
Investors: Peter Vozzo - ICR Healthcare